Humiglim MP2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (50mg), and Pioglitazone (15mg) designed for extended-release administration. This formulation is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). The extended-release formulation ensures a gradual and sustained release of active ingredients, promoting better glycemic control with reduced dosing frequency and potentially minimizing gastrointestinal side effects commonly associated with Metformin. Humiglim MP2 is intended as part of a comprehensive diabetes management plan that includes diet and exercise. Caution is advised in patients with hepatic, renal, or cardiovascular impairment, and regular monitoring of blood glucose, liver function, and hematologic parameters is recommended. This combination therapy should be used under medical supervision to optimize efficacy and minimize adverse effects.